Search This Blog

Thursday, December 3, 2020

Meatpacker Smithfield Foods offers to store COVID-19 vaccines in ultra-cold freezers

 Smithfield Foods, the world’s biggest pork processor, said on Thursday it had offered to help U.S. health officials distribute COVID-19 vaccines and store them in ultra-cold freezers that are in high demand to support a public vaccination campaign.

U.S. states, cities and hospitals are scrambling to buy freezers that can safely store Pfizer’s COVID-19 vaccine at temperatures of minus 70 Celsius (minus 94 Fahrenheit), significantly below the standard for vaccines.

Moderna’s vaccine can be stored at minus 20 Celsius.

Smithfield, owned by China’s WH Group, has multiple “ultra-cold” freezers and will work with local authorities to provide assistance as needed, said Chief Administrative Officer Keira Lombardo, without providing details.

The company is “ready and willing to assist health agencies should storage capacity become constrained,” she said in a statement to Reuters.

Thousands of meatpacking workers employed by Smithfield and rivals like Tyson Foods and JBS USA have been infected with COVID-19. Nearly 20 U.S. meat plants were shut in the spring due to outbreaks, tightening supplies, raising prices and making meatpacking one of the industries most impacted by the pandemic in the United States.

Smithfield may be able to keep Moderna’s vaccine in static freezers that store meat before it is exported or sold, said Chris Hodges, a former senior vice president of business development for the company.

Other “blast” freezers that push cold air on to meat before it is moved into static freezers could potentially get cold enough to hold Pfizer’s version, although it would be very expensive to run them for long periods of time, he said.

“As it becomes more clear that successful vaccines will become available, we have communicated our capabilities and continued willingness to partner with health officials, including with vaccine distribution and storage,” Lombardo said.

Working with health agencies, Smithfield expects it can help distribute vaccines rapidly to food and agricultural workers hit hard by the pandemic, Lombardo said. The company also offered to aid distribution to other essential workers through healthcare offices at its facilities.

Meatpacking workers are considered essential in many states, but not at the top of the list for vaccines, which are expected to be distributed first to healthcare workers and nursing home residents.

Organizations representing food and meat companies have asked U.S. President Trump and President-elect Joe Biden for priority access to vaccines for workers.

Tyson Foods said in an e-mail to Reuters it was closely monitoring the development of vaccines and working with healthcare experts on planning and distribution models for employees.

https://www.reuters.com/article/us-health-coronavirus-vaccine-meatpackin/u-s-meatpacker-smithfield-foods-offers-to-store-covid-19-vaccines-in-ultra-cold-freezers-idUSKBN28D2JW

Moderna to supply up to 125m COVID-19 vaccine doses globally in 1st quarter

 Moderna Inc said on Thursday it expects to have between 100 million and 125 million doses of its experimental COVID-19 vaccine available globally in the first quarter of 2021.

The company said 85 million to 100 million of those doses would be available in the United States, with 15 million to 25 million available outside the country.

The first-quarter doses are within the 500 million to up to 1 billion doses the company expects to manufacture globally in 2021, Moderna said.

Results from an early-stage trial showed that the vaccine, mRNA-1273, produced high levels of binding and neutralizing antibodies that declined slightly over time, but remained elevated in all participants three months after the booster vaccination, the company said.

https://www.reuters.com/article/us-health-coronavirus-moderna/moderna-to-supply-up-to-125-million-covid-19-vaccine-doses-globally-in-first-quarter-idUSKBN28D3FA

Uber asks CDC to deem ride-hail drivers essential for COVID-19 vaccine distribution

 Uber Technologies Inc on Thursday asked the U.S. Centers for Disease Control and Prevention to designate its ride-hail and delivery drivers as non-health essential workers entitled for early COVID-19 vaccine distribution.

The company in a letter to the CDC’s Advisory Committee on Immunization Practices said its drivers continued to provide critical transportation for essential workers and allowed others to stay home and order food.

https://www.reuters.com/article/us-health-coronavirus-uber-vaccine/uber-asks-u-s-cdc-to-consider-ride-hail-drivers-essential-for-covid-19-vaccine-distribution-idUSKBN28E04L

Moderna: Study shows vaccine candidate indicates durable immunity

 

  • Moderna (NASDAQ:MRNA) says participants in the Phase 1 study led by the National Institute of Allergy and Infectious Diseases of mRNA-1273, its COVID-19 vaccine candidate, retained high levels of neutralizing antibodies through 119 days following the first vaccination and 90 days following the second vaccination.
  • The interim Phase 1 data suggests that mRNA-1273 "can generate durable neutralizing antibodies across all age groups including in older and elderly adults," Moderna Chief Medical Officer Tal Zaks says. "These data give us further optimism to expect that the high level of efficacy recently demonstrated by mRNA-1273 to prevent COVID-19 disease will be durable."
  • The company reaffirms it expects to have 100M-125M doses available globally in Q1 2021, including 85M-100M in the U.S. and 15M-25M available outside the U.S.
  • The update follows Moderna's Nov. 30 announcement that the mRNA-1273's primary efficacy analysis of the Phase 3 study conducted on 196 cases confirmed the high efficacy observed at the first interim analysis, with the data analysis indicating a vaccine efficacy of 94.1%.
  • https://seekingalpha.com/news/3641591-moderna-says-study-shows-vaccine-candidate-indicates-durable-immunity

Effective post-exposure prophylaxis of Covid-19 is associated with use of hydroxychloroquine

 

Prospective re-analysis of a public dataset incorporating novel data

David M WisemanPierre KorySamir A SaidiDan Mazzucco

Janssen in Rolling Submission for Single-dose COVID-19 Vaccine Candidate to European Medicines Agency

Janssen-Cilag International N.V., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, has initiated a rolling submission with the European Medicines Agency (EMA) for its investigational single-dose vaccine candidate for the prevention of COVID-19.

The EMA’s Committee for Medicinal Products for Human Use (CHMP) enabled a rolling review of the investigational single-dose Janssen COVID-19 vaccine candidate based principally on positive non-clinical data showing that the vaccine candidate elicits a robust immune response, as demonstrated by neutralising antibodies. 

Janssen will continue to work in close collaboration with the EMA’s CHMP to complete the rolling review process and to facilitate a conditional Marketing Authorisation Application (MAA) when appropriate. In addition to the EMA, Janssen is in discussions with other regulatory authorities worldwide, as it prepares to initiate regulatory review processes for use of its investigational single-dose COVID-19 vaccine candidate during the pandemic response period.

https://www.janssen.com/emea/sites/www_janssen_com_emea/files/jj_announces_initiation_of_rolling_submission_for_its_single_dose_janssen_covid19_vaccine_candidate_with_the_ema.pdf

Fauci apologizes for casting doubt over UK's approval of Pfizer vaccine

 Anthony Fauci, the top U.S. infectious diseases expert, apologized on Thursday after casting doubt over the rigor of the British regulators who approved the Pfizer vaccine against COVID-19 and said he had faith in their work.

“There really has been a misunderstanding, and for that I’m sorry, and I apologize for that,” Fauci said in an interview with BBC television, after his earlier comments on CBS were broadcast in Britain and received prominent coverage.

“I do have great faith in both the scientific community and the regulatory community in the UK,” Fauci said.

“I did not mean to apply any sloppiness (to the UK regulatory process) even though it came out that way,” he said. “So if it did, I just want to set the record straight. I have a great deal of confidence in what the UK does both scientifically and from a regulatory standpoint.”

https://www.reuters.com/article/us-health-coronavirus-britain-fauci-apol/fauci-apologizes-for-casting-doubt-over-uks-approval-of-pfizer-vaccine-idUSKBN28D3AH